Capnomed receives the Promising Startups in Asia Award at the ACES Awards 2020
STUTTGART, Germany, Nov. 11, 2020 /PRNewswire/ -- A new, inventive cutting-edge therapy (PIPAC - Pressurized IntraPeritoneal Aerosol Chemotherapy) is bringing hope to millions of cancer patients across the globe -- including Asia. This treatment is performed using Capnomed's uniquely designed, patented, single-use device: CapnoPen®. As a recognition, Capnomed is acknowledged as Promising Startups in Asia by MORS Group.
Capnomed® is a successful medical technology company which develops innovative processes using medical aerosols. Capnomed is devoted to the mission of improving the health and well-being of Cancer patients using their high-end technologies, such as the specialized laparoscopic nebulizer and drug carrier solutions. The company head office, production unit and research facilities are located in Germany. At Capnomed, technical expertise of medical devices (engineering) and drug carriers (pharma) are combined to develop modern-era cancer treatment. At the core of their success is a team of engineers, pharma scientists and regulatory experts.
Patients benefiting from this new treatment typically suffer from advanced gastric, colorectal and ovarian cancers that have spread or originated in the peritoneum. Peritoneal cancers are difficult to treat satisfactorily using currently available treatments such as systemic chemotherapy, radiation etc. They pose a high financial burden, mental and physical stress to patients. In contrast, PIPAC offers a quick, easy, safe administration of medical drugs at cancer target site through aerosolization of drug, exhibiting significant improvement in the quality of life of patients and low side effects compared to standard chemotherapy.
Prof. Jimmy So from National University of Singapore confirms the urgent need for better cancer treatment options: "Peritoneal carcinomatosis is a common advanced cancer with poor prognosis. PIPAC is a novel technique to deliver chemotherapy more effectively to the peritoneum. We introduced PIPAC to Asia in 2016. Together with Capnomed, we continue to develop PIPAC through scientific research and education."
Capnomed is currently expanding in Asia and supplying its technology to leading medical centers in the region. Singapore is the first Asian country to adopt PIPAC in Asia by engaging in clinical trials. Alongside, Capnomed is rapidly expanding in other Asian countries like India, China, Malaysia, South Korea, Thailand or Philippines. Capnomed is committed in bridging scientific and technical knowledge between East and West to bring the state-of-the-art cancer treatment options to Asian populations.
Mr. Stéphane Laurent
Regional Head -- Asia & Middle East, Capnomed GmbH
+49 741 27065635
SOURCE MORS Group
Upcoming Life Sciences Events
- March 2021
- 2nd Annual European HealthTech CEO Forum
- Pharma-Biotech Product & Company Valuation Course
- 14th Annual European Life Sciences CEO Forum